Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Basit Öğe Kaydı
dc.contributor.authorGoss, G. D.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorLee, K. H.
dc.contributor.authorGoker, E.
dc.contributor.authorFelip, E.
dc.date.accessioned2020-12-01T12:09:03Z
dc.date.available2020-12-01T12:09:03Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstract[No abstract available]en_US
dc.identifier.doi10.1016/j.jtho.2019.09.165
dc.identifier.endpageS1185en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue11en_US
dc.identifier.startpageS1185en_US
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2019.09.165
dc.identifier.urihttps://hdl.handle.net/11454/63277
dc.identifier.volume14en_US
dc.identifier.wosWOS:000494945000074en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectlung SCCen_US
dc.subjectafatiniben_US
dc.subjecterlotiniben_US
dc.subjectsecond-lineen_US
dc.titleSecond-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trialen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu